HIF-2α inhibitors are used to treat renal cell carcinoma and certain other types of cancers related to von Hippel-Lindau (VHL) disease. These medications work by blocking the activity of hypoxia-inducible factor 2 alpha (HIF-2α), a protein that helps cancer cells grow and survive in people with renal cell carcinoma or VHL disease. HIF-2α inhibitors are available in oral form. An example of this type of medication is Welireg (belzutifan). You can take these medications as prescribed to manage your condition effectively.